CureVac N.V. Equity-NMS: CVAC

$4.66 0 (February 28, 2026)

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.
Powered by Vested Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
Previous close :$4.66
1Y :50%
5Y :-95.19%

Compare with Other Stocks

Frequently Asked Questions

What is the share price of CureVac N.V. today?

CureVac N.V. (CVAC) share price as of February 28, 2026, is $4.66. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of CureVac N.V.?

Yes, Indian Investors can invest in the CureVac N.V. (CVAC) Share by opening an international trading account with Angel One.

How can I purchase CureVac N.V. shares in India?

Purchasing CureVac N.V. (CVAC) share from India can be done by:
  1. Directly: By opening an international trading account with Angel One. The process would include KYC verification.
    The account activation takes a few minutes to a few hours, after which you can start buying CureVac N.V. (CVAC) by making deposits in US dollars.
  2. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of CureVac N.V.?

Yes, you can purchase fractional shares of CureVac N.V. (CVAC) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of CureVac N.V.?

The market capitalization of CureVac N.V. on February 28, 2026, is $0.

In which sector CureVac N.V. belongs?

CureVac N.V. operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in CureVac N.V. stocks?

In order to invest in CureVac N.V. (CVAC) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

About CureVac N.V.

CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).